Hormone Therapy Today: Perception, Attitudes, and Evidence
James A. Simon, MD, CCD, FACOG—Co-Chair
Clinical Professor of Obstetrics & Gynecology
George Washington University School of Medicine
Washington, DC
Dr. Simon is a consultant to Abbott Laboratories, Ascend Therapeutics, Barr Pharmaceuticals, Inc., Berlex/Bayer Healthcare Pharmaceuticals, BioSante Pharmaceuticals, Depomed Inc., Duramed Pharmaceuticals, Inc., Esprit Pharma, Inc., GlaxoSmithKline, Hoffmann-LaRoche, Johnson & Johnson Family of Companies, KV Pharmaceuticals Co., Meditrina Pharmaceuticals Inc., Merck & Co., Inc., Nanma/Tripharma, Noven Pharmaceuticals, Inc., Organon, Pfizer Inc., Procter & Gamble Pharmaceuticals, Inc., QuatRx Pharmaceuticals Company, Solvay Pharmaceuticals Inc., TAP Pharmaceuticals, Inc., Trinity Marketing, VIVUS, Inc., Warner Chilcott, and Wyeth. He has received funding for clinical grants from Amgen, Inc., Barr, Berlex-Bayer, Besins Pharma GmbH, BioSante, Boehringer Ingelheim Corporation, Duramed, Endoceutics, GlaxoSmithKline, Ortho-McNeil, Nanma/Tripharma, Novartis, Pfizer, Procter & Gamble, Trinity Marketing, VIVUS, and Wyeth. In addition, he has received honoraria for speakers' meetings and advisory boards from Abbott, Ascend, sanofi-aventis, U.S. LLC, Berlex/Bayer, Duramed, Esprit Pharma, GlaxoSmithKline, Hoffmann-LaRoche, Merck, Novogyne Pharmaceutical Inc., Ortho-McNeil Pharmaceutical, Inc., Pfizer, Solvay, Warner Chilcott, and Wyeth. Intrauterine Contraception: The Evidence Refutes the Myths
Philip D. Darney, MD, MSc—Co-Chair
Professor and Chief of Obstetrics and Gynecology
San Francisco General Hospital
University of California
San Francisco, California
Dr. Darney has received honoraria for speakers' bureau meetings from Bayer Healthcare Pharmaceuticals. He intends to reference unlabeled/unapproved uses of levonorgestrel-releasing intrauterine system (LNG-IUS) in his article. The Role and Appropriate Use of the Modern IUD
Jeffrey T. Jensen, MD, MPH
Leon Speroff Professor of Obstetrics and Gynecology
Oregon Health & Science University
Portland, Oregon
Dr. Jensen has received funding for clinical grants from Bayer, Novartis Pharmaceuticals Corporation, Warner Chilcott, and Wyeth Pharmaceuticals. He is a consultant to Bayer, Novartis, and Wyeth and has received honoraria from Bayer and Wyeth. He intends to reference unlabeled/unapproved uses of LNG-IUS in his article.
|
Women's health practitioners must be prepared to provide counseling and treatment for women of childbearing age who desire reversible contraception and for older women who require treatment for postmenopausal symptoms. In the United States today, the most commonly used contraceptive methods are oral contraceptives and surgical sterilization. However, clinicians should be knowledgeable about-and women should be advised about the availability of-longer-term, reversible methods that are safe, convenient, and highly effective, namely, intrauterine contraception (IUC). In this supplement, clinicians receive updated information about the two devices that are currently available to American women: The copper IUD (copper T) and the levonorgestrel-releasing intrauterine system (LNG-IUS), including which women are suitable candidates for this method, the mechanisms of action of the two IUC types, and the noncontraceptive benefits associated with the hormone-releasing system. Regarding women beyond childbearing years-that is, postmenopausal women-concerns that arose from the publication of data from large-scale epidemiologic studies such as the Women's Health Initiative caused many women to avoid beginning, or to stop taking, postmenopausal hormone therapy (HT). Since that time, further research and analysis of the previously available data allow clinicians to view all of the evidence in context. This supplement provides an overview of both the risks of HT and the established benefits regarding modulation of vasomotor symptoms and overall improvement in quality of life in at-risk women. Specifically covered are current misconceptions about HT use and risks for breast cancer and cardiovascular disease, scientific data that address lingering concerns about side effects, and therapeutic strategies that are in line with current U.S. Food and Drug Administration guidelines for using lower-dose estrogen alternatives.
|
